(Q51724218)

10 April 2018

title

Proof of concept: a PhRMA position paper with recommendations for best practice. (English)

1 reference

10 April 2018

1 reference

M E Cartwright

1

1 reference

10 April 2018

S Cohen

2

1 reference

10 April 2018

J C Fleishaker

3

1 reference

10 April 2018

S Madani

4

1 reference

10 April 2018

J F McLeod

5

1 reference

10 April 2018

B Musser

6

1 reference

10 April 2018

S A Williams

7

1 reference

10 April 2018

language of work or name

English

0 references

publication date

3 February 2010

1 reference

10 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

10 April 2018

volume

87

1 reference

10 April 2018

issue

3

1 reference

10 April 2018

page(s)

278-285

1 reference

10 April 2018

The price of innovation: new estimates of drug development costs

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

The value of improving the productivity of the drug development process: faster times and better decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Comparison of treatment effects between animal experiments and clinical trials: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

The ultimate model organism: progress in experimental medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Strategic approach to fit-for-purpose biomarkers in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Simulation of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

Model-based development of gemcabene, a new lipid-altering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

The value, qualification, and regulatory use of surrogate end points in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.286

21 January 2018

Identifiers

DOI

10.1038/CLPT.2009.286

1 reference

10 April 2018

1 reference

10 April 2018